Rheumatology

Your Article Summary

See Latest Articles

Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct
Journal of Rheumatology, 10/15/09

Mease P et al. – Consensus was reached as follows: (1) Greater than 70% of OMERACT participants agreed that pain, tenderness, fatigue, patient global, multidimensional function and sleep disturbance domains should be measured in all FM clinical trials; dyscognition and depression should be measured in some trials; and stiffness, anxiety, functional imaging, and cerebrospinal fluid biomarkers were identified as domains of research interest. (2) FM domain outcome measures have generally proven to be reliable, discriminative, and feasible. More sophisticated and comprehensive measures are in development, as is a responder index for FM. (3) Increasing numbers of objective markers are being developed for FM assessment. (4) Cognitive dysfunction assessment by self–assessed and applied outcome measures is being developed. In conclusion, a multidimensional symptom core set is proposed for evaluation of FM in clinical trials. Research on improved measures of single domains and composite measures is ongoing.

Today in Chr Fatigue/Fibromyalgia...keeping you current

Receive free subspecialty "5-minute updates" via email

Advances in fibromyalgia treatment: understanding endogenous pain modulation
International Journal of Clinical Rheumatology, 11/09/09

Recreational Exercise in Rheumatic Diseases
International Journal of Sports Medicine, 10/30/09

Is fatigue an inflammatory variable in rheumatoid arthritis (ra)? analyses of fatigue in ra, osteoarthritis, and fibromyalgia
Journal of Rheumatology, 11/19/09

See All of Chr Fatigue/Fibromyalgia